An artificial intelligence start-up founded by three insiders at Memorial Sloan Kettering Cancer Center debuted with great fanfare in February, with $25 million in venture capital and the promise that it might one day transform how cancer is diagnosed.
Image: At Memorial Sloan Kettering Cancer Center in Manhattan, doctors and staff objected to a for-profit venture that could be lucrative for a few leading researchers and board members.CreditCreditGabriella Angotti-Jones for The New York Times
